Teva’s Ajovy Claims 28%-30% New Prescription Share In Competitive CGRP Race
Executive Summary
The company said it has captured a roughly 28%-30% share of new prescriptions in the CGRP market with the initial launch of Ajovy, a key future growth driver to offset declining Copaxone sales.